文献速递乳腺癌

乳腺断层合成与超声在乳腺X线阴性致密乳腺中的补充筛查:ASTOUND-2前瞻性对照试验

A prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2).
PubMed 文献 · Eur J Cancer · 2018-10-11

ASTOUND-2是一项多中心前瞻性对照试验,纳入5300例乳腺X线筛查阴性且致密乳腺的无症状女性,独立解读断层合成与超声。超声补充检出更多乳腺癌(增量CDR 4.90/1000次筛查)但假阳性召回率更高(1.0%),断层合成增量CDR为2.83/1000次筛查,假阳性召回率0.30%,两者差异均有统计学意义。

要点

  • 超声补充筛查增量CDR高于断层合成(4.90 vs 2.83/1000次筛查,P=0.015)。
  • 断层合成假阳性召回率显著低于超声(0.30% vs 1.0%,P<0.001)。
  • 补充筛查检出的29例乳腺癌中27例为浸润性,平均大小14.2mm,6例有淋巴结转移。

核心结论

  • 在乳腺X线筛查阴性的致密乳腺女性中,超声补充筛查检出更多乳腺癌但假阳性召回率高于断层合成,提示补充影像筛查存在结局权衡。

研究设计与样本

  • 多中心前瞻性对照试验(ASTOUND-2),纳入5300例参加意大利乳腺筛查服务、乳腺X线阴性且致密乳腺的无症状女性,中位年龄50岁(四分位距43-79),所有参与者均独立接受断层合成和超声检查。

主要发现

  • 补充筛查额外检出29例乳腺癌(27例浸润性,2例原位),其中12例断层合成和超声均检出,3例仅断层合成检出,14例仅超声检出。
  • 断层合成增量CDR为2.83/1000次筛查(95%CI 1.58-4.67),超声增量CDR为4.90/1000次筛查(95%CI 3.21-7.19),P=0.015。
  • 补充检出乳腺癌平均大小14.2mm(标准差7.8mm),6例有淋巴结转移。
  • 增量假阳性召回率为1.22%(95%CI 0.91%-1.49%),断层合成0.30%与超声1.0%之间差异显著(P<0.001)。

临床怎么用

  • 对乳腺X线筛查阴性且致密乳腺的女性,选择断层合成或超声作为补充筛查时需权衡癌症检出收益与假阳性召回风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased risk of breast cancer (BC) and increased risk of an interval BC at mammography screening are associated with high mammographic density. Adjunct imaging detects additional BCs not detected at mammography screening in women with dense breasts. AIM: The aim is to estimate the incremental cancer detection rate (CDR) and false-positive recall for each of tomosynthesis and ultrasound, as adjunct screening modalities in women with mammography-negative dense breasts. METHODS: A multicentre prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2) recruited asymptomatic women attending Italian breast screening services. All participants had independently interpreted tomosynthesis and ultrasound. Outcomes were ascertained from excision histopathology or completed assessment. Paired binary data were compared using McNemar's test. RESULTS: We recruited 5300 screening participants with median age of 50 (interquartile range 43-79) years who had negative mammography and dense breasts (April 2015-September 2017). Adjunct screening detected 29 additional BCs (27 invasive, 2 in situ): 12 detected on both tomosynthesis and ultrasound, 3 detected only on tomosynthesis, 14 detected only on ultrasound. Incremental CDR for tomosynthesis (+15 cancers) was 2.83/1000 screens (95% confidence interval [CI]: 1.58-4.67) versus ultrasound (+26 cancers) with an incremental CDR of 4.90/1000 screens (95% CI: 3.21-7.19), P = 0.015. Mean size of these cancers was 14.2 mm (standard deviation: 7.8 mm), and six had nodal metastases. Incremental false-positive recall was 1.22% (95% CI: 0.91%-1.49%) and differed significantly between tomosynthesis (0.30%) and ultrasound (1.0%), P < 0.001. CONCLUSIONS: Ultrasound detected more BCs but caused more false positives than tomosynthesis, underscoring trade-offs in screening outcomes when adjunct imaging is used for screening dense breasts.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Tagliafico AS, Mariscotti G, Valdora F, et al. A prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2). Eur J Cancer. 2018. PMID: 30316869. doi:10.1016/j.ejca.2018.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。